Related Experiment Video

Updated: Apr 12, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

835

Et and diabetic nephropathy: preclinical and clinical studies

Elena Gagliardini1, Carlamaria Zoja2, Ariela Benigni3

  • 1Unit of Advanced Microscopy, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.

Seminars in Nephrology
|May 13, 2015
PubMed

Insights

Diabetic kidney disease is rising globally. Targeting endothelin-1 (ET-1) with ETA-receptor antagonists shows promise for renoprotection beyond current therapies.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy incidence is increasing worldwide.
  • Current therapies offer only partial renoprotection for diabetic kidney disease.
  • Endothelin-1 (ET-1) plays a pathogenic role in diabetic nephropathy progression.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the endothelin-1 pathway in diabetic nephropathy.
  • To evaluate the renoprotective effects of ETA-receptor antagonists in preclinical models of diabetes.

Main Methods:

  • Review of experimental studies on endothelin-1 and diabetic nephropathy.
  • Analysis of data from animal models of type 1 and type 2 diabetes treated with ETA-selective antagonists.

Main Results:

  • Endothelin-1 (ET-1) activation, particularly via ETA receptors, contributes to renal injury, inflammation, and fibrosis.
  • ETA-selective antagonists demonstrated renoprotective effects in animal models of diabetes.
  • These findings support the use of ETA-receptor antagonists as an add-on therapy.

Conclusions:

  • Targeting the ET-1 pathway, specifically ETA receptors, offers a novel therapeutic strategy for diabetic nephropathy.
  • ETA-receptor antagonists show potential for improving renoprotection in diabetic patients.
  • Further clinical investigation is warranted for ETA-receptor antagonists combined with renin-angiotensin system blockade.
Keywords:
Diabetic nephropathydual inhibition of endothelin-converting enzymeendothelin-receptor antagonistsneutral endopeptidaserenin-angiotensin system inhibitors

More Related Videos

Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.9K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.0K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
645
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
515
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K